The Obesity ETF (SLIM) Holdings & Expense Ratio

이 페이지는 영어 원문에서 AI로 기계 번역되었습니다. 영어 버전이 기준입니다. 영어 버전 읽기

정보 제공만을 목적으로 합니다. 재정적 조언이 아닙니다.

빠른 답변

The Obesity ETF (SLIM) has a 0.35% expense ratio and $12M in assets under management. Holdings and weights below are as of Mar 15, 2026.

In the stored portfolio snapshot, the largest listed holding is Novo Nordisk A/S ADR (NVO) at 19.95%, and the largest sector allocation is Healthcare at 91.9%.

Obesity ETF (SLIM) ETF — Price, Holdings & Analysis

ETF 개요

SLIM aims to capture the performance of companies globally that are expected to benefit from the increasing prevalence of obesity. The ETF tracks the Solactive Obesity Index, investing at least 80% of its net assets in its constituent stocks. This targeted approach results in a concentrated portfolio, with a significant allocation to the healthcare sector (91.9%). The fund's top holdings include Novo Nordisk A/S ADR (19.95%), a major player in diabetes and obesity care, and DexCom Inc (13.38%), a company specializing in continuous glucose monitoring systems. Other significant holdings include Fresenius Medical Care AG & Co. KGaA (8.64%) and Insulet Corp (6.27%). SLIM offers investors a way to invest in companies involved in addressing and managing obesity and related conditions.

위험 지표

SLIM's non-diversified nature and concentrated sector allocation introduce specific risks. The heavy weighting in healthcare (91.9%) means the fund's performance is highly correlated with the performance of that sector. A significant portion of the fund is allocated to its top holdings, with Novo Nordisk A/S ADR comprising nearly 20% of the portfolio, indicating concentration risk. The fund's beta of 0.70 suggests it is less volatile than the overall market. The expense ratio of 0.35% will create a drag on performance over time, although this is in line with similar thematic ETFs. Investors should be aware of these factors when considering an investment in SLIM. Past performance does not guarantee future results.

베타: 0.70

운용보수율

0.35%

SLIM은(는) 무엇을 보유하고 있나요?

보유 종목	비중
Novo Nordisk A/S ADR (NVO)	19.95%
DexCom Inc (DXCM)	13.38%
Fresenius Medical Care AG & Co. KGaA (FME.DE)	8.64%
Insulet Corp (PODD)	6.27%
Tandem Diabetes Care Inc (TNDM)	4.97%
Fisher & Paykel Healthcare Corp Ltd (FPH.NZ)	4.90%
DaVita Inc (DVA)	4.55%
Abiomed Inc (ABMD)	3.83%
Herbalife Nutrition Ltd (HLF)	3.17%
iRhythm Technologies Inc (IRTC)	3.16%

보유 종목 및 비중: 2026년 3월 15일 기준. 이 펀드 데이터는 45일 이상 지났습니다. 최신 보유 종목은 발행사에서 확인하세요.

펀드는 어떻게 배분되어 있나요?

섹터	비중
헬스케어	91.9%
필수소비재	4.3%
경기소비재	3.9%

배당수익률

0.57%

iShares Morningstar Small-Cap Growth ETF (JKK) — 0.06% expense ratio
ARK Innovation ETF (ARKK) — 0.75% expense ratio
Invesco QQQ Trust, Series 1 (QQQ) — 0.18% expense ratio
State Street Energy Select Sector SPDR ETF (XLE) — 0.08% expense ratio
WisdomTree Emerging Markets ESG Fund (DVEM) — 0.32% expense ratio
Goldman Sachs ActiveBeta Emerging Markets Equity ETF (GEM) — 0.59% expense ratio
State Street SPDR Dow Jones Industrial Average ETF Trust (DIA) — 0.16% expense ratio
State Street Technology Select Sector SPDR ETF (XLK) — 0.08% expense ratio

질문 및 답변

What is SLIM and what does it track?

The Obesity ETF (SLIM) seeks to replicate the performance of the Solactive Obesity Index. This index is designed to track companies globally that are positioned to profit from servicing the obese population.

These companies include those involved in biotechnology, pharmaceuticals, healthcare, medical devices, weight loss programs, weight loss supplements, and plus-sized apparel.

What is the expense ratio for SLIM?

The expense ratio for SLIM is 0.35%. This means that for every $10,000 invested in the fund, $35 is deducted annually to cover operating expenses.

While it's difficult to determine a precise category average for such a niche thematic ETF, the expense ratio is comparable to other specialized equity ETFs. The expense ratio as a factor impacting the overall return of the fund over time may be worth researching.

What are the top holdings in SLIM?

SLIM's top holdings reflect its focus on companies involved in obesity-related products and services.

As of 2026-03-15, the top three holdings are Novo Nordisk A/S ADR (19.95%), a leading pharmaceutical company in diabetes and obesity care; DexCom Inc (13.38%), which specializes in continuous glucose monitoring systems; and Fresenius Medical Care AG & Co.

Is SLIM a good long-term investment?

Whether SLIM is a suitable long-term investment depends on an individual's investment goals and risk tolerance. The fund offers targeted exposure to a specific theme, which can lead to concentrated risk.

SLIM's performance will be influenced by the growth of the obesity-related market and the success of its constituent companies.

How does SLIM compare to similar ETFs?

SLIM is unique in its specific focus on companies profiting from the obesity market. While there aren't many directly comparable ETFs, some broader healthcare ETFs may have overlapping holdings.

SLIM's expense ratio of 0.35% is competitive within the thematic ETF space. With AUM of $0.01 billion, SLIM is a relatively small ETF, which can impact liquidity and trading costs.

Does SLIM pay dividends?

Yes, SLIM pays dividends. The current dividend yield for SLIM is 0.57%. This means that for every $100 invested in the fund, investors can expect to receive $0.57 in dividend payments annually.

The dividend yield may fluctuate based on the performance of the underlying holdings and the fund's distribution policy.

면책 조항: 이 콘텐츠는 정보 제공만을 목적으로 하며 투자 조언을 구성하지 않습니다. 항상 자체 조사를 수행하고 재정 고문과 상담하십시오.

데이터는 정보 제공만을 목적으로 제공됩니다.

이 페이지는 기계가 작성했으며, 페이지별 사람 검수는 거치지 않았습니다. 편집 관리는 체계 차원에서 이루어집니다: 규칙과 출처를 점검하며, 개별 페이지는 점검하지 않습니다.